Class: Viral DNA polymerase inhibitor Status: Under testing, emergency use possible Target: Viral DNA polymerase Administration: Injection Notes: Repurposed drug approved against herpes viruses. It inhibits viral replication by selectively inhibiting viral DNA polymerases. It also incorporates into viral DNA, inhibiting viral DNA synthesis during replication.
Class: Viral DNA polymerase inhibitor Status: Approved (FDA 2021) Target: Viral DNA polymerase Administration: Oral Notes: Is a prodrug of cidifovir. The compound conjugated to a lipid is designed to facilitates entry into cells, allowing higher intracellular and lower plasma concentrations.
Class: viral phospholipase inhibitor Status: Approved (FDA 2018) Administration: Oral Target: Envelope phospholipase F13 Notes: Prevents the second envelopment of the mature virion in the Golgi, preventing cell-to-cell transmission of the virus.